Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 1.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eiko Lifesciences Limited reported audited FY25 results with an unmodified (clean) opinion from statutory auditor PSV Jain & Associates. On a standalone basis, revenue grew about 16.3% to INR 3,249.18 lakhs (vs INR 2,792.93 lakhs in FY24), while profit after tax jumped roughly 132% to INR 174.08 lakhs (vs INR 75.15 lakhs), lifting EPS to INR 1.34 from INR 0.73. This is the first year of consolidated reporting, including new subsidiary Eikovivify Logistics (which began operations during FY25), taking consolidated FY25 revenue to INR 3,766.40 lakhs and consolidated PAT to INR 231.86 lakhs. An exceptional item of INR 34.12 lakhs was booked for interest received from shareholders on delayed payment of the rights issue call money. Operating cash flow was negative on both standalone (INR -204.61 lakhs) and consolidated (INR -732.57 lakhs) bases, largely driven by a sharp increase in trade receivables and inventories. The board also appointed M/s Shravan Gupta & Associates as Secretarial Auditor for 5 years and M/s NP Rajput & Co as Internal Auditor for FY26.
Sharp jump in profitability and the addition of a new logistics revenue stream are positives for shareholders, but the sizeable negative operating cash flow points to working-capital stress that investors should monitor. Overall, earnings momentum is strong even as cash conversion lags.